Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 76 results
A stethoscope and blood pressure cuff in a clinical setting

May 18, 2026

Cardio Diagnostics Holdings (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

Cardio Diagnostics Holdings is addressing the critical need for early detection and intervention in cardiovascular disease through a comprehensive suite of AI-powered solutions.Recent research highlights the pressing need for advanced tools that can identify cardiovascular disease (CVD) risks earlier, which is vital for personalized intervention strategies. Cardio Diagnostics Holdings (CDIO) is responding by developing a range of solutions that leverage artificial intelligence, epigenetics, and
A genomic sample on a lab bench with imaging equipment in the background.

May 18, 2026

MedGenome to expand integrated diagnostics access across Mumbai suburbs

MedGenome has announced a strategic collaboration with Siddhi Diagnostics & Research Centre (SDRC) to enhance access to integrated diagnostics in the suburban areas of Mumbai. This partnership aims to combine genomics with advanced imaging technologies, thereby improving precision diagnostics in regions that traditionally lack such resources.MedGenome, known for its focus on genomics-driven diagnostics, is poised to strengthen its presence in the Mumbai suburbs through this collaboration. SDRC,
VO2 Max testing device in a clinical setting

May 14, 2026

Year-Long Preventive Health Programs

Fountain Life has introduced the APEX Membership, a comprehensive year-long preventive health initiative integrating advanced diagnostics and AI technology.This program includes a variety of assessments such as full body and brain MRIs, low-dose lung CTs, retinal scans, whole genome sequencing, and more. Notably, it features two new services: Functional Movement and Mobility Range Assessment, which utilize 3D motion capture and clinical-grade VO2 Max testing. These additions aim to fill a crucia
A minimalist trophy silhouette representing the MedTech Award in a dark color scheme.

May 11, 2026

MedTech Award Highlights Healthcare Informatics Breakthrough

The recent MedTech Award highlights a significant advancement in healthcare informatics, particularly through Ambry's CARE platform, which has garnered attention for its role in enhancing patient care and operational efficiency.Ambry was awarded this prestigious recognition on May 7, 2026, selected from over 4,700 global entries. This accolade is seen as a validation of the platform's effectiveness in improving patient outcomes, which is increasingly important in a competitive market. The award
Stylized DNA helix and test tube illustration

May 11, 2026

Stronger Q1 Results And New AI Oncology Tests Could Be A Game Changer For Caris Life Sciences (CAI)

Caris Life Sciences has reported impressive first-quarter results, showcasing a significant revenue increase and the launch of new AI-driven oncology tests that could reshape its market position.In May 2026, Caris Life Sciences announced a revenue of $216.17 million for Q1, a substantial rise from $120.92 million in the same period last year. The company also improved its net loss to $0.51 million and received MolDX approval for its Caris ChromoSeq whole genome assay. Additionally, it launched t
A flat design of a liquid biopsy tube with a drop of liquid, symbolizing molecular diagnostics.

May 10, 2026

Qiagen N.V. stock (NL0012169213): Life science tools firm eyes growth in molecular diagnostics and p

Qiagen N.V. is strategically enhancing its portfolio in molecular diagnostics, focusing on growth opportunities in oncology, infectious diseases, and precision medicine.As a prominent entity in the life sciences tools and diagnostics market, Qiagen N.V. specializes in sample preparation technologies, assay kits, and bioinformatics software. The company's commitment to advancing next-generation sequencing and liquid biopsy techniques positions it favorably within the evolving landscape of genomic
Flat design illustration of a test tube and DNA strand representing cancer diagnostics

May 9, 2026

Should Caris’s Q1 Revenue Surge and New AI Cancer Tests Require Action From Caris Life Sciences (CAI) Investors?

Caris Life Sciences has reported a significant revenue increase in Q1 2026, driven by new AI-based cancer diagnostic tests, prompting a reevaluation of its investment potential.In early May 2026, Caris Life Sciences announced a first-quarter revenue of $216.17 million, a substantial rise from $120.92 million in the same period last year. The company also reported a narrowed net loss of $0.51 million, down from $102.58 million. This financial growth coincides with the introduction of the AI-drive
A flat illustration of a cell with a highlighted biomarker in a minimalist design.

May 7, 2026

Israeli-founded AI biotech Immunai expands AstraZeneca cancer collaboration

Immunai, an AI biotech founded in Israel, has announced an expanded collaboration with AstraZeneca focused on oncology, potentially yielding up to $37.5 million over the next two years.This new agreement extends their multi-year partnership, allowing AstraZeneca to utilize Immunai's AMICA-OS AI operating system. This platform integrates clinical immunology data at a single-cell level with advanced AI models, aimed at enhancing oncology drug development through biomarker discovery, patient strati
A DNA sequencing sample on a lab bench in a dimly lit laboratory.

May 7, 2026

DNAnexus Wins MedTech Breakthrough’s PharmaTech Innovation Award

DNAnexus has been recognized with the PharmaTech Innovation Award at the 10th annual MedTech Breakthrough Awards, highlighting its significant contributions to precision medicine through its AI-driven orchestration platform.This award acknowledges DNAnexus as a pivotal player in the biopharma landscape, particularly for its ability to convert complex multimodal data into actionable scientific insights. The MedTech Breakthrough Awards program, known for its rigorous evaluation process, assessed o
A minimalist illustration of a DNA strand representing genomic diagnostics.

May 6, 2026

Moonlight AI secures €2.8 million to advance genomic diagnostics

Moonlight AI, a Swiss startup focusing on AI-driven cancer diagnostics, has successfully secured €2.8 million in Seed funding to enhance its innovative technology.This funding round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with additional support from N&V Capital and existing investor QAI Ventures. Founded in 2022, Moonlight AI aims to democratize genomic data access, facilitating precise cancer diagnostics without the need for expensive Next-Generation Sequencing
A blood sample and microscope in a dimly lit lab setting

May 6, 2026

Swiss startup Moonlight AI raises €2.8 million to turn routine blood and cytology imaging into genomic insights

Swiss startup Moonlight AI has secured €2.8 million in Seed funding to enhance diagnostic capabilities through innovative image analysis technology.Moonlight AI, established in 2022, is focused on developing AI-driven solutions for clinical diagnostics, specifically aiming to transform routine blood and cytology imaging into actionable genomic insights. The recent funding round was co-led by notable investors including Lotus One Investment and VP Venture Partners, with the goal of democratizing
A minimalist illustration of a breast and a pathology slide on a solid background.

May 5, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris Life Sciences has introduced Caris MI Clarity, a groundbreaking AI-powered test aimed at predicting both early and late distant recurrence risks in postmenopausal patients diagnosed with HR-positive/HER2-negative, node-negative early-stage breast cancer. This innovative test promises to deliver results to physicians within three business days, significantly faster than traditional methods.The Caris MI Clarity test utilizes a proprietary dataset comprising thousands of breast cancer samples